Impact of poor-quality medicines in the 'developing' world
- PMID: 20117849
- PMCID: PMC2845817
- DOI: 10.1016/j.tips.2009.11.005
Impact of poor-quality medicines in the 'developing' world
Abstract
Since our ancestors began trading several millennia ago, counterfeit and substandard medicines have been a recurring problem, with history punctuated by crises in the supply of anti-microbials, such as fake cinchona bark in the 1600s and fake quinine in the 1800s. Unfortunately this problem persists, in particular afflicting unsuspecting patients in 'developing' countries. Poor-quality drugs are a vital (but neglected) public health problem. They contribute to a 'crevasse' between the enormous effort in therapeutic research and policy decisions and implementation of good-quality medicines.
2009 Elsevier Ltd. All rights reserved.
References
-
- Caudron J.M. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop. Med. Int. Health. 2008;13:1062–1072. - PubMed
-
- Newton P.N. Counterfeit anti-infective medicines. Lancet Inf. Dis. 2006;6:602–613. - PubMed
-
- Wondemagegnehu, E. (1999) Counterfeit and substandard drugs in Myanmar and Viet Nam. WHO Report. WHO/EDM/QSM/99.3. Geneva: WHO
-
- Primo-Carpenter, J. and McGinnis, M. (2009) A matrix of drug quality reports on USAID-assisted countries by the USP Drug Quality and Information Program, 2009 (http://www.usp.org/pdf/EN/dqi/ghcDrugQualityMatrix.pdf). Accessed 3 October 2009
-
- IMPACT (2006) Counterfeit Medicines: an update on estimates. (http://www.who.int/medicines/services/counterfeit/impact/TheNewEstimates...). Accessed 3 October 2009
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
